(NASDAQ:HGSI) Trading Higher on Positive Study - Stock Alert
Stock Market Alert
Dallas, TX 10/20/2009 02:38 PM GMT (TransWorldNews)
Subscribe to our Online Stock News Alerts offered by http://www.pennystockmoneytrain.com/
Human Genome Sciences (NASDAQ:HGSI) reported progress in two Phase III trials of belimumab, under investigation as a treatment for seropositive patients with systemic lupus. The drug "plus standard of care achieved a clinically and statistically significant improvement in patient response rate" compared with placebo plus standard of care, the companies, based in Rockville, Md., and London respectively, said in a statement on Tuesday. "No new drug for lupus has been approved by regulatory authorities in more than 50 years," they said in the statement.
Shares of HGSI are up 3% at $21.59 on 890K shares being traded within few minutes of trade.
Human Genome Sciences (HGS) is a commercially focused biopharmaceutical company. The Company has three products in late-stage clinical development: Albuferon for chronic hepatitis C, LymphoStat-B for systemic lupus erythematosus and ABthraxtm for inhalation anthrax.
ABOUT PennyStockMoneyTrain.com
Penny Stock Money Train provides free stock market news alerts on those stocks that are poised to make big gains. PennyStockMoneyTrain also tracks small cap pennystocks that could be on the brink of a massive breakout. If you want to feature a company on our website, please contact us at info[at]PennyStockMoneyTrain.com
info@pennystockmoneytrain.com
www.pennystockmoneytrain.com
Email Article to a friend
|
View Profile
Visit Blogs
|
NEWS ALERTS
Receive alerts for
HGSI
to your inbox.
Sign up for TransWorldNews Alerts
TransWorldNews, Inc. and its affiliate sites disclaim all liability for information and content provided by clients and appearing within their news and press releases.
